These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 21892623)

  • 1. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
    Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of peptide receptor radionuclide therapy with
    Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y
    Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
    Bodei L; Cremonesi M; Ferrari M; Pacifici M; Grana CM; Bartolomei M; Baio SM; Sansovini M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1847-56. PubMed ID: 18427807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment.
    Svensson J; Berg G; Wängberg B; Larsson M; Forssell-Aronsson E; Bernhardt P
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):947-55. PubMed ID: 25655484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
    Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
    Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.
    Paganelli G; Sansovini M; Ambrosetti A; Severi S; Monti M; Scarpi E; Donati C; Ianniello A; Matteucci F; Amadori D
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1845-51. PubMed ID: 24615468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twins in spirit part IV - [
    Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
    Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
    Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized
    Del Prete M; Buteau FA; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetry and pharmacokinetics of [
    Schürrle SB; Eberlein U; Ansquer C; Beauregard JM; Durand-Gasselin L; Grønbæk H; Haug A; Hicks RJ; Lenzo NP; Navalkissoor S; Nicolas GP; Pais B; Volteau M; Wild D; McEwan A; Lassmann M
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2428-2441. PubMed ID: 38528164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.